Vaxfab Enterprises Limited Submits SEBI Compliance Certificate for Q4FY26

1 min read     Updated on 14 Apr 2026, 03:40 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Vaxfab Enterprises Limited submitted its SEBI compliance certificate under Regulation 74(5) for Q4FY26, covering the period from January 1, 2026 to March 31, 2026. The certificate, issued by registrar Skyline Financial Services Private Limited, confirms no physical share certificates were received for dematerialization during the quarter. The filing was authorized by Director Nishant Gandhi and submitted to BSE Limited and The Calcutta Stock Exchange Limited on April 14, 2026.

powered bylight_fuzz_icon
37707049

*this image is generated using AI for illustrative purposes only.

Vaxfab enterprises Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing, dated April 14, 2026, was submitted to BSE Limited and The Calcutta Stock Exchange Limited as part of the company's regulatory compliance obligations.

Regulatory Compliance Details

The certificate was submitted under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation requires companies to report on dematerialization activities during each quarter.

Parameter: Details
Quarter Covered: January 1, 2026 to March 31, 2026
Regulation: SEBI Regulation 74(5)
Filing Date: April 14, 2026
Registrar: Skyline Financial Services Private Limited

Certificate Confirmation

Skyline Financial Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 1, 2026. The certificate specifically states that no physical share certificates were received for dematerialization of equity shares during the quarter ended March 31, 2026.

The certificate was signed by Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, and submitted to the company for onward transmission to the stock exchanges.

Company Information

Vaxfab Enterprises Limited operates under CIN L52291GJ1983PLC093146 with its registered office located at Office 304, 305, Scarlet Gateway, B/H Ashwaraj Bunglows, Prahladnagar Corporate Road, Manekbag, Ahmedabad, Gujarat. The company is listed on BSE Limited and The Calcutta Stock Exchange Limited with script code 015064 and security code 542803.

Filing Authorization

The regulatory filing was authorized by Nishant Gandhi, Director of Vaxfab Enterprises Limited (DIN: 09250907), who digitally signed the submission on April 14, 2026. The filing confirms the company's adherence to SEBI's quarterly reporting requirements for depositories and participants.

Historical Stock Returns for Vaxfab Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.32%+9.34%+17.86%+45.59%+280.77%+111.54%

What factors might be contributing to the absence of dematerialization requests for Vaxfab's shares, and could this indicate limited trading activity?

How might Vaxfab's compliance track record impact its eligibility for future regulatory benefits or streamlined reporting processes?

Will the company's consistent zero dematerialization pattern affect its relationship with registrar Skyline Financial Services or lead to cost optimization discussions?

Vaxfab Enterprises Reports Q3FY26 Results with Standalone Profit Despite Consolidated Loss

2 min read     Updated on 13 Apr 2026, 10:02 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Vaxfab Enterprises Limited reported Q3FY26 results showing standalone profit of ₹22.98 lakhs versus previous year's loss of ₹356.99 lakhs, while consolidated operations recorded a loss of ₹323.52 lakhs. Revenue from operations increased to ₹1566.29 lakhs from ₹914.39 lakhs year-over-year for standalone business. The auditors issued qualified opinions citing documentation deficiencies, non-compliance with MSMED Act requirements, absence of gratuity provisions, and lack of impairment assessments under Indian Accounting Standards.

powered bylight_fuzz_icon
37643529

*this image is generated using AI for illustrative purposes only.

Vaxfab Enterprises Limited announced its unaudited financial results for the quarter ended December 31, 2025, presenting a mixed performance with standalone operations turning profitable while consolidated results remained in the red. The Board of Directors approved these results at their meeting held on February 14, 2026.

Financial Performance Overview

The company's financial performance for Q3FY26 showed significant variation between standalone and consolidated operations:

Metric Standalone Q3FY26 Consolidated Q3FY26 Standalone Q3FY24 Consolidated Q3FY24
Revenue from Operations ₹1566.29 lakhs ₹1566.29 lakhs ₹914.39 lakhs ₹1906.37 lakhs
Total Revenue ₹1566.29 lakhs ₹1229.61 lakhs ₹928.10 lakhs ₹1920.17 lakhs
Net Profit/(Loss) ₹22.98 lakhs ₹(323.52) lakhs ₹(356.99) lakhs ₹(354.82) lakhs
Basic EPS ₹0.27 ₹(0.39) ₹(4.25) ₹(0.42)

Operational Analysis

Revenue from operations for the quarter reached ₹1566.29 lakhs, representing a substantial increase from ₹914.39 lakhs in the corresponding quarter of the previous year for standalone operations. The company's total expenses for standalone operations were ₹1526.98 lakhs compared to ₹1346.33 lakhs in Q3FY24.

The standalone operations achieved a profit before tax of ₹39.31 lakhs, marking a significant turnaround from the loss of ₹418.23 lakhs recorded in the same quarter last year. After accounting for tax expenses of ₹16.36 lakhs, the company reported a net profit of ₹22.98 lakhs.

Consolidated Results

Consolidated operations, which include subsidiary Eklingji Tradelink Private Limited, showed a different picture. Despite similar revenue from operations, the consolidated entity reported a net loss of ₹323.52 lakhs for Q3FY26. Total consolidated revenue was ₹1229.61 lakhs due to negative other income of ₹336.68 lakhs.

Auditor Qualifications

The statutory auditors, Chandabhoy & Jassoobhoy Chartered Accountants, issued qualified opinions on both standalone and consolidated financial results, highlighting several areas of concern:

Key Audit Issues

  • Documentation Deficiencies: Inadequate supporting documents for trade receivables and payables, with external confirmations not obtained
  • MSMED Compliance: Lack of requisite details for classification of creditors under the Micro, Small, and Medium Enterprises Development Act, 2006
  • Employee Benefits: No provision recognized for gratuity liability and absence of actuarial valuation as required under Ind AS 19
  • Impairment Assessment: Company has not carried out impairment assessment of financial assets under Expected Credit Loss model prescribed under Ind AS 109
  • Loan Documentation: Unsecured loans granted and received without formal agreements or confirmations from parties

Share Capital and EPS

The company maintained its paid-up equity share capital at ₹840.00 lakhs with a face value of ₹1 per share. Basic and diluted earnings per share for standalone operations improved to ₹0.27 from ₹(4.25) in the corresponding quarter of the previous year.

Regulatory Compliance

The financial results were prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015, and comply with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors on February 14, 2026.

Historical Stock Returns for Vaxfab Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
-0.32%+9.34%+17.86%+45.59%+280.77%+111.54%

What strategic measures will Vaxfab implement to address the significant consolidated losses and improve subsidiary performance?

How will the company resolve the multiple auditor qualifications, particularly the documentation deficiencies and compliance gaps?

Can Vaxfab sustain its standalone profitability momentum in upcoming quarters given the operational challenges highlighted?

More News on Vaxfab Enterprises

1 Year Returns:+280.77%